<DOC>
	<DOCNO>NCT02253173</DOCNO>
	<brief_summary>This study ass safety efficacy new formulation vaginal estradiol treatment symptom vulvar vaginal atrophy postmenopausal woman .</brief_summary>
	<brief_title>Estradiol Vaginal Softgel Capsules Treating Symptoms Vulvar Vaginal Atrophy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Postmenopausal female subject age 40 75 year ( time randomization ) least : 12 month spontaneous amenorrhea ( woman &lt; 55 year age history hysterectomy without bilateral oophorectomy prior natural menopause must follicle stimulate hormone ( FSH ) level &gt; 40 mIU/mL ) , OR 6 month spontaneous amenorrhea follicle stimulate hormone ( FSH ) level &gt; 40mlU/mL OR At least 6 week postsurgical bilateral oophorectomy . 2 . â‰¤5 % superficial cell vaginal cytological smear 3 . Vaginal pH &gt; 5.0 4 . Moderate severe symptom vaginal pain associate sexual activity consider bothersome vaginal symptom subject screen visit 1A . 5 . Moderate severe symptom vaginal pain associate sexual activity screen visit 1B . 6 . Onset moderate severe dyspareunia postmenopausal year . 7 . Subjects sexually active ( i.e . sexual activity vaginal penetration within approximately 1 month screen visit 1A ) . 8 . Subjects anticipate sexual activity ( vaginal penetration ) conduct trial . 9 . For subject intact uterus : Subjects must acceptable result evaluable screen endometrial biopsy . 10 . Subjects Body Mass Index ( BMI ) less equal 38 kg/m2 . BMI value round nearest integer ( ex . 32.4 round 32 , 26.5 round 27 ) . 11 . In opinion investigator , subject comply protocol high probability complete study . 1 . Use follow : 1 . Oral estrogen , progestin , androgen , SERMcontaining drug product within 8 week screen visit 1A ( enter washout ) ; 2 . Use transdermal hormone product within 4 week screen visit 1A ( enter washout ) ; 3 . Use vaginal hormone product ( ring , cream , gel ) within 4 week screen visit1A ( enter washout ) ; 4 . Use intrauterine progestin within 8 week screen visit 1A ( enter washout ) ; 5 . Use progestin implants/injectables estrogen pellets/injectables within 6 month screen visit 1A ( enter washout ) ; 6 . Use vaginal lubricant moisturizers within 7 day screen visit 1B vaginal pH assessment . 2 . A history active presence clinically important medical disease might confound study detrimental subject , examples include : 1 . Hypersensitivity estrogens ; 2 . Endometrial hyperplasia ; 3 . Undiagnosed vaginal bleeding ; 4 . Have history chronic liver kidney dysfunction/disorder ( e.g. , Hepatitis C chronic renal failure ) ; 5 . Thrombophlebitis , thrombosis thromboembolic disorder ; 6 . Cerebrovascular accident , stroke , transient ischemic attack ; 7 . Myocardial infarction ischemic heart disease ; 8 . Malignancy treatment malignancy , within previous 5 year , exception basal cell carcinoma skin squamous cell carcinoma skin . A history estrogen dependent neoplasia , breast cancer , melanoma gynecologic cancer , time , excludes subject ; 9 . Endocrine disease ( except control hypothyroidism control noninsulin dependent diabetes mellitus ) . 3 . Recent history know alcohol drug abuse . 4 . History sexual abuse spousal abuse , opinion PI , may interfere subject 's assessment vaginal pain sexual activity . 5 . Current history Heavy smoking ( 15 cigarette per day ) use ecigarettes . 6 . Use intrauterine device within 12 week screen visit 1A . 7 . Use investigational drug within 60 day screen visit 1A . 8 . Any clinically important abnormality screen physical exam , assessment , ECG , laboratory test , : 1 . Unresolved cervical cytologic smear report atypical glandular cell undetermined significance ( AGUS ) atypical squamous cell undetermined significance ( ASCUS ) . Cervical cytologic smear report lowgrade squamous intraepithelial lesion ( SIL ) great , CIN1 great , report dysplasia ; Subjects ASCUS eligible high risk human papilloma virus ( HPV ) result negative . 2 . Unresolved finding suspicious malignancy breast exam ; incomplete mammogram result ( BIRADS 0 ) unresolved finding suggestive malignant change finding require short interval followup prestudy mammogram ( subject must mammography result BIRADS 1 2 enroll . ) Mammogram may perform within 9 month prior Visit 2 ( randomization ) documentation available . ( The site must obtain copy official report subject 's study file , must verify mammogram available need additional assessment ) ; 3 . In subject intact uterus : screen endometrial biopsy sample find primary pathologist endometrial tissue insufficient diagnosis , endometrium identify , tissue identify . ( With approval Medical Monitor , screen endometrial biopsy may repeat ) ; 4 . In subject intact uterus : endometrial biopsy report one central pathologist screen one following : Endometrial hyperplasia endometrial cancer , proliferative endometrium , weakly proliferative endometrium , disorder proliferative pattern ; OR Endometrial polyp hyperplasia , glandular atypia degree ( e.g. , atypical nucleus ) cancer ; 5 . Vulvar vaginal inflammatory condition contact allergic dermatitis , lichen sclerosis pathological finding ; 6 . Presence suspicious vulvar vaginal lesion dysplasia , malignancy pathology atrophy ; 7 . Painful genital wart localize area ulceration ; 8 . A history active , chronic pelvic pain ; 9 . Interstitial cystitis ; 10 . Serum alanine aminotransferase ( ALT ) serum aspartate aminotransferase ( AST ) great 1.5 time upper limit normal laboratory use ; 11 . Fasting total cholesterol great 300 mg/dL ( 7.77 mmol/L ) triglycerides great 300 mg/dL ( 3.39 mmol/L ) ; 12 . Fasting blood glucose great 125 mg/dL ( 6.94 mmol/L ) hemoglobin A1C great equal 6.5 % ; 13 . Uncontrolled hypertension ; subject elevate sit blood pressure , great 140 mm Hg systolic great 90 mm Hg diastolic may use 2 antihypertensive medication treatment hypertension ; 14 . Clinically significant abnormal 12lead ECG ( myocardial infarction finding suggestive ischemia ) 9 . Be know pregnant positive urine pregnancy test . ( Note : A pregnancy test require subject bilateral tubal ligation , bilateral oophorectomy , hysterectomy , 55 year old great experienced cessation menses least 1 year . 10 . Current use marijuana .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>VVA</keyword>
	<keyword>Painful Sex</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>